Background: In modern ophthalmology antiangiogenic treatment of diabetic macular edema is a first–line therapy. More new antiangiogenic drugs are being created in order to improve treatment results. But due to the advent of new drugs, there are more questions about their effect on the patient's cornea.Aims: The aim of the study was to study the effect of intravitreal administration of brolucizumab on the corneal endothelium in patients with diabetic macular edema.Methods: 56 patients (56 eyes) were included in the prospective study: 14 men and 42 women with different stages of diabetic retinopathy with diabetic macular edema. All patients underwent endothelial microscopy using the Tomey EM-4000 endothelial microscope, estimated: CD – the number of endothelial cells per 1 mm2; CCT is the central thickness of the cornea; CV is the coefficient of variation; 6A is the proportion of hexagonal cells. All study participants received intravitreal injections of brolucizumab in a volume of 0.05 ml.Results: before intravitreal injections, the indices of the central corneal thickness and the number of endothelial cells per 1 mm2 were 549.68 ± 30,123 microns and 2378.95 ± 393.3 cells/mm2, respectively. After a course of antiangiogenic DME therapy, the central thickness of the cornea was 548.18 ± 30.56 microns, and the number of endothelial cells per 1 mm2 was 2382.34 ± 424.90 cells/mm2. The indicators CV and 6A before the start of intravitreal injections were 36.93 ± 5% and 46.82 ± 6.3%, respectively, after the introduction of the "loading dose" drugs, the average values were 37.86 ± 4.3% and 45.8 ± 6.3%. Changes in all indicators were not static significant.Conclusions: The use of brolucizumab as therapy in patients with DME did not cause a negative effect on the cornea, there were no statistically significant changes in the corneal indicators.